Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 15590691
Singhirunnusorn P, et al. (2005) Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-beta-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. J Biol Chem 280, 7359-68 15590691
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1 (human), TAB1 (human) increase
TNF increase
siRNA TNF TAK1 (human) inhibit treatment-induced increase
siRNA TNF TAB1 (human) inhibit treatment-induced increase
siRNA TNF TAB2 (human) inhibit treatment-induced increase
hypertonic_buffer increase
siRNA hypertonic_buffer TAK1 (human) inhibit treatment-induced increase
siRNA hypertonic_buffer TAB1 (human) inhibit treatment-induced increase
siRNA hypertonic_buffer TAB2 (human) inhibit treatment-induced increase

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAK1 (human), TAB1 (human) increase
TNF increase
siRNA TNF TAK1 (human) inhibit treatment-induced increase
siRNA TNF TAB1 (human) inhibit treatment-induced increase
siRNA TNF TAB2 (human) inhibit treatment-induced increase
hypertonic_buffer increase
siRNA hypertonic_buffer TAK1 (human) inhibit treatment-induced increase
siRNA hypertonic_buffer TAB1 (human) inhibit treatment-induced increase
siRNA hypertonic_buffer TAB2 (human) inhibit treatment-induced increase

S423-p - TAB1 (human)
Modsite: QMVNGAHsASTLDEA SwissProt Entrez-Gene
Orthologous residues
TAB1 (human): S423‑p, TAB1 iso2 (human): S423‑p, TAB1 (mouse): S421‑p, TAB1 (rat): S421‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
Downstream Regulation
Effect of modification (function):  activity, inhibited, phosphorylation
Comments:  inhibits phosphorylation of TAK1

T431-p - TAB1 (human)
Modsite: ASTLDEAtPTLTNQs SwissProt Entrez-Gene
Orthologous residues
TAB1 (human): T431‑p, TAB1 iso2 (human): T431‑p, TAB1 (mouse): T429‑p, TAB1 (rat): T429‑p
Characterization
Methods used to characterize site in vivo electrophoretic mobility shift, mutation of modification site
Relevant cell lines - cell types - tissues:  HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
Downstream Regulation
Effect of modification (function):  activity, inhibited, phosphorylation
Comments:  inhibits phosphorylation of TAK1

T187-p - TAK1 (human)
Modsite: CDIQtHMtNNKGsAA SwissProt Entrez-Gene
Orthologous residues
TAK1 (human): T187‑p, TAK1 (mouse): T187‑p, TAK1 iso3 (mouse): T187‑p, TAK1 (rat): T187‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE TAK1 (human) activation of upstream enzyme, transfection of inactive enzyme, phospho-antibody, transfection of wild-type enzyme, pharmacological activator of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TAB1 (human) increase
TAB2 (human) increase
TNF increase
siRNA TNF TAB1 (human) inhibit treatment-induced increase
siRNA TNF TAB2 (human) inhibit treatment-induced increase
SB203580 TNF augment treatment-induced increase
siRNA TNF P38A (human) augment treatment-induced increase
hypertonic_buffer no change compared to control
SB203580, hypertonic_buffer increase
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced, phosphorylation
Effect of modification (process):  transcription, altered
Comments:  phosphorylation of p38

S192-p - TAK1 (human)
Modsite: HMtNNKGsAAWMAPE SwissProt Entrez-Gene
Orthologous residues
TAK1 (human): S192‑p, TAK1 (mouse): S192‑p, TAK1 iso3 (mouse): S192‑p, TAK1 (rat): S192‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial), HeLa (cervical)
Cellular systems studied:  cell lines
Species studied:  human
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced, phosphorylation
Comments:  phosphorylation of TAK1 T187